PTBP2 and chronic myelogenous leukemia, BCR-ABL1 positive: Enhanced engraftment and extramedullary infiltration in the transplantation model indicate that PTBP2 contributes to more aggressive disease, making it a potential marker for advanced-stage CML or blast crisis.